Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
13 pending office actions • 5 art units • 12 examiners • 0 of 13 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Inovio Pharmaceuticals Inc. has 13 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 12 distinct examiners across 5 distinct art units, showing a broad distribution of active prosecution rather than a single examiner-centered docket. That structure may reflect multiple technical or application groupings within the portfolio.
ALLEN, MICHAEL D is the busiest examiner, with 2 pending matters. The remaining actions are therefore spread among other examiners, making centralized status tracking important for response timing, claim strategy, and identification of recurring substantive issues across related applications.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (23%) |
| §103 only | 4 (31%) |
| §112 only | 2 (15%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 2 (15%) |
| Multi-statute (no §101) | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 2 | 31.9% | +48.8% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| ZAMORY, JUSTIN L | 1 | 72.7% | +17.6% |
| HILL, MYRON G | 1 | 66.1% | +20.7% |
| FARRAR, LAUREN PENG | 1 | 78.7% | +15.6% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| FOLEY, SHANON A | 1 | 73.3% | +18.2% |
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18768701 | Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom | CHESTNUT, BARRY A | — |
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | — |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | — |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | ALAM, DANYAL HASSAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17474389 | Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy | NATARAJAN, MEERA | 15d overdue |
| 18765882 | OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS | ALLEN, MICHAEL D | — |
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | — |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | — |
| 18493512 | Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods | FARRAR, LAUREN PENG | — |
| 18486708 | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same | KINSEY WHITE, NICOLE ERIN | — |
| 18300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | ALLEN, MICHAEL D | — |
| 18048776 | COMPOSITIONS AND METHODS FOR TREATING ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | FOLEY, SHANON A | — |
| Art Unit | Apps |
|---|---|
| 1671 | 5 |
| 1672 | 3 |
| 3783 | 3 |
| 1643 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18768701 | Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom | CHESTNUT, BARRY A | 1672 | §101§103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18765882 | OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS | ALLEN, MICHAEL D | 1671 | §112 | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | 3783 | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | 1671 | §101§103 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18493512 | Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods | FARRAR, LAUREN PENG | 3783 | §103 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18486708 | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same | KINSEY WHITE, NICOLE ERIN | 1672 | §103§112DP | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | ALAM, DANYAL HASSAN | 1672 | §101§103 | Final Rejection | — | Pending | Apr 14, 2023 |
| 18300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | ALLEN, MICHAEL D | 1671 | §112 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18048776 | COMPOSITIONS AND METHODS FOR TREATING ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | FOLEY, SHANON A | 1671 | DP | Final Rejection | — | Pending | Oct 21, 2022 |
| 17474389 | Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy | NATARAJAN, MEERA | 1643 | §103DP | Final Rejection | 15d overdue | Pending | Sep 14, 2021 |
| 17221032 | COMPOSITIONS AND METHODS FOR TREATING VULVAR DYSPLASIA | ZOU, NIANXIANG | 1671 | §103 | Non-Final OA | — | Pending | Apr 02, 2021 |
| 17063977 | PD1 AND PDL1 ANTIBODIES AND VACCINE COMBINATIONS AND USE OF SAME FOR IMMUNOTHERAPY | HINES, JANA A | 1645 | §103 | Non-Final OA | 15d | Pending | Oct 06, 2020 |
| 16804707 | VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD | VU, QUYNH-NHU HOANG | 3783 | §103 | Final Rejection | 37d overdue | Pending | Feb 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInovio Pharmaceuticals Inc. has 13 pending office actions as of October 2026, spread across 5 art units and 12 examiners.
Michael D Allen has the most, with 2 of Inovio Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
